Your browser doesn't support javascript.
loading
M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
Gil-Moreno, Antonio; Alonso-Alconada, Lorena; Díaz-Feijoo, Berta; Domingo, Santiago; Vilar, Ana; Hernández, Alicia; Gilabert, Juan; Llueca, Antoni; Torné, Aureli; de Santiago, Javier; Carbonell-Socias, Melchor; Lago, Víctor; Arias, Efigenia; Sampayo, Victoria; Siegrist, Jaime; Chipirliu, Anca; Sánchez-Iglesias, Jose Luis; Pérez-Benavente, Assumpció; Padilla-Iserte, Pablo; Santacana, Maria; Matias-Guiu, Xavier; Abal, Miguel; Lopez-Lopez, Rafael.
Afiliación
  • Gil-Moreno A; Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain. Electronic address: agil@vhebron.net.
  • Alonso-Alconada L; Nasasbiotech, S.L., A Coruña, Spain.
  • Díaz-Feijoo B; Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain.
  • Domingo S; Department of Gynecology Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Vilar A; Department of Gynecology, University Hospital of Santiago de Compostela, Spain.
  • Hernández A; Department of Gynecology, University Hospital La Paz, Madrid, Spain.
  • Gilabert J; Department of Obstetrics and Gynecology, Hospital General Universitario de Valencia, Universidad de Valencia, Valencia, Spain.
  • Llueca A; Department of Obstetrics and Gynecology, Hospital General Universitari de Castelló, Castelló de la Plana, Spain.
  • Torné A; Institute Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • de Santiago J; Department of Gynecology, MD Anderson Cancer Center, Madrid, Spain.
  • Carbonell-Socias M; Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain.
  • Lago V; Department of Gynecology Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Arias E; Department of Gynecology, University Hospital of Santiago de Compostela, Spain.
  • Sampayo V; Department of Gynecology, University Hospital of Santiago de Compostela, Spain.
  • Siegrist J; Department of Gynecology, University Hospital La Paz, Madrid, Spain.
  • Chipirliu A; Department of Obstetrics and Gynecology, Hospital General Universitario de Valencia, Universidad de Valencia, Valencia, Spain.
  • Sánchez-Iglesias JL; Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain.
  • Pérez-Benavente A; Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain.
  • Padilla-Iserte P; Department of Gynecology Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Santacana M; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain.
  • Matias-Guiu X; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain.
  • Abal M; Nasasbiotech, S.L., A Coruña, Spain; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), CIBERONC, Santiago de Compostela, Spain.
  • Lopez-Lopez R; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), CIBERONC, Santiago de Compostela, Spain. Electronic address: rafael.lopez.lopez@sergas.es.
Gynecol Oncol ; 161(3): 681-686, 2021 06.
Article en En | MEDLINE | ID: mdl-33795131
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Procedimientos Quirúrgicos de Citorreducción / Carcinoma Epitelial de Ovario / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Observational_studies Límite: Adult / Aged / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Procedimientos Quirúrgicos de Citorreducción / Carcinoma Epitelial de Ovario / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Observational_studies Límite: Adult / Aged / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Año: 2021 Tipo del documento: Article